Grant has extensive expertise running patent oppositions including responsibility for 5 concurrent patent oppositions making up the Australian component of the CRISPR gene editing global litigation. Grant also has particular expertise in securing extensions of term on pharmaceutical patents and advising on patent validity and infringement. He is also a litigation support expert having acted in revocation proceedings in the Federal Court, including to the blockbuster anti-PD-1 antibody, Keytruda.

​

Prior to entering the patent profession, Grant enjoyed a 15-year career in medical research, that included a PhD directed to antibody engineering and immunoglobulin polyreactivity. He has also engaged in breast cancer research, DNA vaccine development, as well as working for biotech start-ups in London, Switzerland and Sydney.

​

Grant is Vice President of the Institute of Patent and Trademark Attorneys of Australia (IPTA), the peak body representing Australian patent and trade mark attorneys. In this role, Grant is the convenor of the Governance Committee as well as convenor of the Public Relations Committee, which leads IPTA’s political engagement (lobbying) strategy, particularly in relation to proposed changes to Australian patent legislation and innovation policy.